Related Experiment Videos
Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate
T T Muhonen1, T A Wiklund, C P Blomqvist
1Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
This study found that the combination chemotherapy regimen mitomycin, mitoxantrone, and methotrexate (MMM) caused significant leukopenia and thrombocytopenia in cancer patients. Mitomycin appeared to be the primary contributor to this toxicity.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Chemotherapy regimens are crucial in treating various cancers, including breast and colon cancer.
- Understanding the toxicity profiles of combination therapies is essential for patient management.
- Mitomycin, mitoxantrone, and methotrexate (MMM) is a combination regimen used in cancer treatment.
Purpose of the Study:
- To evaluate the toxicity profile of the MMM chemotherapy regimen in cancer patients.
- To identify the specific drugs contributing to hematological toxicities.
- To determine the duration of recovery from these toxicities.
Main Methods:
- A cohort of 28 patients with breast or colon cancer received the MMM regimen.
- Incidence and severity of leukopenia and thrombocytopenia were monitored.
- Time to recovery to World Health Organization (WHO) grade 0 for these hematological parameters was recorded.
Main Results:
- 28 patients (26 breast cancer, 2 colon cancer) were treated with MMM.
- 50% of patients experienced grade III-IV leukopenia, and 29% experienced grade III-IV thrombocytopenia.
- Median recovery times to WHO grade 0 were 62 days for leukopenia and 128 days for thrombocytopenia.
Conclusions:
- The MMM regimen is associated with significant hematological toxicities, specifically leukopenia and thrombocytopenia.
- Mitomycin appears to play a critical role in the frequency and duration of these toxicities.
- Further investigation into mitomycin's role in chemotherapy-induced myelosuppression is warranted.